CRISPRの世界市場：2025年～2033年

世界のCRISPRの市場規模は2024年に39億3,000万米ドルとなりました。同市場は、2033年には159億2,000万米ドルに達し、予測期間の2025年～2033年のCAGRは16.8%となる見込みです。

CRISPR（Clustered Regularly Interspaced Short Palindromic Repeats）は、DNAの正確な改変を可能にする遺伝子編集技術であり、医療、農業、バイオテクノロジーなどの分野に革命をもたらしています。Cas9酵素を使用することで、CRISPRは研究者が驚くほど正確に遺伝物質を追加、削除、改変することを可能にします。

その応用には、遺伝性疾患の遺伝子治療、がん研究、作物の改良、疾患モデルの作成などがあります。CRISPRキットと消耗品は、研究者にとって不可欠なツールであり、ワークフローを簡素化し、遺伝子編集実験へのアクセスを向上させる。これらのキットは、アカデミック・ラボや臨床ラボでますます使用されるようになり、イノベーションを促進しています。さらに、特定の遺伝子を標的とするガイドRNAのコレクションであるCRISPRライブラリーは、大規模な遺伝子機能研究や創薬をサポートします。

CRISPR市場は、遺伝子編集技術の急速な進歩によって大きく牽引されています。遺伝子編集技術は、腫瘍学、免疫学、希少疾患などの様々な分野において、より正確で効率的かつスケーラブルな治療ソリューションを可能にしています。このような技術革新は、CRISPRの潜在的な用途を拡大するだけでなく、その変革の可能性を利用しようとする大手バイオ医薬品企業からの多額の投資を引き寄せています。

例えば、AstraZenecaは2023年11月、戦略的提携の一環として、臨床段階のバイオテクノロジー企業であるCellectisに2億4,500万米ドルを投資すると発表しました。この提携は、Cellectisが独自に開発した遺伝子編集技術と製造能力を活用することで、次世代治療薬の開発を加速させることを目的としています。この提携は、新規の細胞・遺伝子治療法の設計をサポートするもので、遺伝子編集の進歩が、CRISPRや広範な遺伝子治療領域における大手企業のプレゼンス拡大を促していることを浮き彫りにしています。

さらに、この技術がより洗練され、利用しやすくなるにつれて、より多くの臨床試験、研究室でのより広範な採用、さらには個別化医療での使用の機会が開かれます。この絶え間ない技術革新は、CRISPRが達成できることの限界を押し広げるだけでなく、市場内のさらなる投資、協力、成長を促進します。

高度なCRISPRツールや技術に関連する高コストは、CRISPR市場の成長に大きな障壁として作用すると予想されます。この技術は計り知れない可能性を秘めていますが、洗練された装置、試薬、熟練した人材の取得と維持にかかる費用は、特に小規模な研究機関、新興企業、発展途上地域の組織にとっては、その利用を制限する可能性があります。このような経済的制約は、学術的・商業的環境におけるCRISPRの採用を遅らせ、広範な実験、革新、実施を妨げる可能性があります。

さらに、特に予算が厳しいヘルスケアシステムにおいては、コスト要因が臨床応用を遅らせ、CRISPRに基づく治療のスケーラビリティを制限する可能性があります。

当レポートでは、世界のCRISPR市場について調査し、市場の概要とともに、製品タイプ別、用途別、エンドユーザー別、地域別動向、競合情勢、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 市場のイントロダクションと範囲

第2章 経営者の洞察と重要なポイント

第3章 市場力学

• 影響要因
  • 促進要因
  • 抑制要因
  • 機会
  • 影響分析

第4章 戦略的洞察と業界展望

• 市場のリーダーとパイオニア
• 最新の開発とブレークスルー
• 規制と償還の情勢
• ポーターのファイブフォース分析
• サプライチェーン分析
• 特許分析
• SWOT分析
• アンメットニーズとギャップ
• 市場参入と拡大のための推奨戦略
• シナリオ分析ベストケース、ベースケース、ワーストケースの予測
• 価格分析と価格動向

第5章 CRISPR市場（製品タイプ別）

• CRISPRキットと消耗品
• CRISPRライブラリ
• その他

第6章 CRISPR市場（用途別）

• 創薬と薬剤開発
• 農業
• その他

第7章 CRISPR市場（エンドユーザー別）

• 製薬会社
• バイオテクノロジー企業
• 学術研究機関
• その他

第8章 CRISPR市場、地域別市場分析と成長機会

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他
• 南米
  • ブラジル
  • アルゼンチン
  • その他
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他
• 中東・アフリカ

第9章 競合情勢と市場ポジショニング

• 競合状況の概要と主要市場参入企業
• 市場シェア分析とポジショニングマトリックス
• 戦略的パートナーシップ、合併・買収
• 製品ポートフォリオとイノベーションにおける主な発展
• 企業ベンチマーク

第10章 企業プロファイル

• Thermo Fisher Scientific, Inc.
• 会社概要
• 製品ポートフォリオ
• 財務概要
• 主な発展
• SWOT分析
• Merck KGaA
• Agilent Technologies, Inc.
• GenScript
• Creative Biogene
• Bio-Rad Laboratories, Inc.
• Takara Bio Inc.
• QIAGEN
• Eurofins Genomics
• Synthego

第11章 仮定と調査手法

第12章 付録

The global CRISPR market reached US$ 3.93 billion in 2024 and is expected to reach US$ 15.92 billion by 2033, growing at a CAGR of 16.8% during the forecast period 2025-2033.

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a gene-editing technology that allows precise modifications to DNA, revolutionizing fields such as medicine, agriculture, and biotechnology. By using the Cas9 enzyme, CRISPR enables researchers to add, remove, or alter genetic material with remarkable accuracy.

Its applications include gene therapy for genetic disorders, cancer research, crop improvement, and the creation of disease models. CRISPR kits and consumables provide essential tools for researchers, simplifying workflows and enhancing the accessibility of gene-editing experiments. These kits are increasingly used across academic and clinical labs, fostering innovation. Additionally, CRISPR libraries, which are collections of guide RNAs targeting specific genes, support large-scale gene function studies and drug discovery.

Market Dynamics: Drivers & Restraints

Rapid Advancements in Gene Editing Technologies

The CRISPR market is being significantly driven by rapid advancements in gene editing technologies, which are enabling more precise, efficient, and scalable therapeutic solutions across various fields, such as oncology, immunology, and rare diseases. These innovations are not only expanding the potential applications of CRISPR but are also attracting substantial investments from major biopharmaceutical companies aiming to harness its transformative potential.

For instance, in November 2023, AstraZeneca announced a $245 million investment in Cellectis, a clinical-stage biotechnology company, as part of a strategic collaboration. This partnership aims to accelerate the development of next-generation therapeutics by leveraging Cellectis' proprietary gene editing technologies and manufacturing capabilities. The collaboration will support the design of novel cell and gene therapies, highlighting how advancements in gene editing are encouraging major players to expand their presence in the CRISPR and broader gene therapy space.

Additionally, as the technology becomes more refined and accessible, it opens up opportunities for more clinical trials, broader adoption in labs, and even use in personalized medicine. This constant innovation not only pushes the boundaries of what CRISPR can achieve but also fuels further investment, collaboration, and growth within the market.

High Costs Associated with Advanced CRISPR Tools and Technologies

The high costs associated with advanced CRISPR tools and technologies are expected to act as a significant barrier to the growth of the CRISPR market. While the technology holds immense promise, the expense involved in acquiring and maintaining sophisticated equipment, reagents, and skilled personnel can limit its accessibility, especially for smaller research institutions, startups, and organizations in developing regions. These financial constraints may slow down the adoption of CRISPR in both academic and commercial settings, hindering widespread experimentation, innovation, and implementation.

Additionally, the cost factor can delay clinical applications and limit the scalability of CRISPR-based treatments, particularly in healthcare systems with tight budgets.

Segment Analysis

The global CRISPR market is segmented based on product type, application, end-user, and region.

Product Type:

CRISPR kits & consumables in the product type segment are expected to dominate the CRISPR market.

The CRISPR kits and consumables segment is expected to hold a dominant share of the market, largely due to their essential role in gene editing research and growing demand across academic, clinical, and industrial settings. These kits provide researchers with ready-to-use tools that simplify complex CRISPR workflows, making the technology more accessible and efficient.

As more laboratories and institutions adopt CRISPR for various applications, from genetic disease research to agricultural improvements, the need for high-quality, reliable kits and consumables continues to rise. Their recurring use in experiments and routine lab work also ensures steady demand, positioning this segment as a key driver of growth in the CRISPR market.

With the growing need and demand for these kits and consumables are being innovated by the market players are innovating to meet the growing demand. For instance, in March 2024, Carolina Biological Supply Company announced an exclusive partnership with the ChristianaCare Gene Editing Institute to produce and distribute the CRISPR in a Box educational kit. Designed for high school students (grades 9-12) and higher education, this affordable, hands-on lab kit includes printed materials and interactive exercises. It offers students an engaging introduction to CRISPR gene editing.

Geographical Analysis

North America is expected to dominate the global CRISPR market.

North America is anticipated to lead the CRISPR space in the coming years, driven by a strong foundation of advanced biotechnology infrastructure, significant investments in genetic research, and supportive regulatory frameworks. The region has a large number of the world's leading biotech companies, academic institutions, and research organizations that are actively exploring CRISPR-based technologies for applications ranging from disease treatment to agriculture.

The growing number of clinical trials utilizing CRISPR technology is significantly boosting demand and driving the CRISPR market in North America. For instance, in September 2024, KSQ Therapeutics (US) recently received FDA clearance for its IND application for KSQ-004EX, a CRISPR-Cas9 engineered tumor-infiltrating lymphocyte (TIL) therapy.

This approval allows the initiation of a Phase 1/2 clinical trial, sponsored by The University of Texas MD Anderson Cancer Center, to evaluate the therapy's safety and efficacy in patients with advanced solid tumors. The increasing clinical validation of CRISPR-based therapies like KSQ-004EX highlights the growing momentum of gene editing in oncology and its expanding role in shaping the North America CRISPR market.

Competitive Landscape

The global market players in the CRISPR market include Thermo Fisher Scientific, Inc., Merck KGaA, Agilent Technologies, Inc., GenScript, Creative Biogene, Bio-Rad Laboratories, Inc., Takara Bio Inc., QIAGEN, Eurofins Genomics, and Synthego, among others.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming pharmaceutical advancements.
• Type Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient Type delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global CRISPR market report will provide approximately 45 tables, 46 figures, and 180 pages.

Target Audience 2024

• Manufacturers: Pharmaceutical, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

• 1.1. Objectives of the Report
• 1.2. Report Coverage & Definitions
• 1.3. Report Scope

2. Executive Insights and Key Takeaways

• 2.1. Market Highlights and Strategic Takeaways
• 2.2. Key Trends and Future Projections
• 2.3. Snippet by Product Type
• 2.4. Snippet by Application
• 2.5. Snippet by End-User
• 2.6. Snippet by Region

3. Dynamics

• 3.1. Impacting Factors
  • 3.1.1. Drivers
    • 3.1.1.1. Rapid Advancements in Gene Editing Technologies.
    • 3.1.1.2. Increasing Demand for Personalized and Targeted Therapies
  • 3.1.2. Restraints
    • 3.1.2.1. High costs Associated with Advanced CRISPR Tools and Technologies
    • 3.1.2.2. Risk of off-target Effects and Unintended Genetic Changes
  • 3.1.3. Opportunity
    • 3.1.3.1. Expanding Use of CRISPR in Drug Discovery, Diagnostics, and Agriculture
  • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

• 4.1. Market Leaders and Pioneers
  • 4.1.1. Emerging Pioneers and Prominent Players
  • 4.1.2. Established leaders with largest selling Brand
  • 4.1.3. Market leaders with established Product
• 4.2. Latest Developments and Breakthroughs
• 4.3. Regulatory and Reimbursement Landscape
  • 4.3.1. North America
  • 4.3.2. Europe
  • 4.3.3. Asia Pacific
  • 4.3.4. South America
  • 4.3.5. Middle East & Africa
• 4.4. Porter's Five Forces Analysis
• 4.5. Supply Chain Analysis
• 4.6. Patent Analysis
• 4.7. SWOT Analysis
• 4.8. Unmet Needs and Gaps
• 4.9. Recommended Strategies for Market Entry and Expansion
• 4.10. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
• 4.11. Pricing Analysis and Price Dynamics

5. CRISPR Market, By Product Type

• 5.1. Introduction
  • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 5.1.2. Market Attractiveness Index, By Product Type
• 5.2. CRISPR kits & Consumables*
  • 5.2.1. Introduction
  • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 5.3. CRISPR Libraries
• 5.4. Others

6. CRISPR Market, By Application

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 6.1.2. Market Attractiveness Index, By Application
• 6.2. Drug Discovery & Development*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Agriculture
• 6.4. Others

7. CRISPR Market, By End-User

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 7.1.2. Market Attractiveness Index, By End-User
• 7.2. Pharmaceutical Companies*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Biotechnology Companies
• 7.4. Academic & Research Institutes
• 7.5. Others

8. CRISPR Market, By Regional Market Analysis and Growth Opportunities

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 8.1.2. Market Attractiveness Index, By Region
• 8.2. North America
  • 8.2.1. Introduction
  • 8.2.2. Key Region-Specific Dynamics
  • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.2.6.1. U.S.
    • 8.2.6.2. Canada
    • 8.2.6.3. Mexico
• 8.3. Europe
  • 8.3.1. Introduction
  • 8.3.2. Key Region-Specific Dynamics
  • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.3.6.1. Germany
    • 8.3.6.2. U.K.
    • 8.3.6.3. France
    • 8.3.6.4. Spain
    • 8.3.6.5. Italy
    • 8.3.6.6. Rest of Europe
• 8.4. South America
  • 8.4.1. Introduction
  • 8.4.2. Key Region-Specific Dynamics
  • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.4.6.1. Brazil
    • 8.4.6.2. Argentina
    • 8.4.6.3. Rest of South America
• 8.5. Asia-Pacific
  • 8.5.1. Introduction
  • 8.5.2. Key Region-Specific Dynamics
  • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.5.6.1. China
    • 8.5.6.2. India
    • 8.5.6.3. Japan
    • 8.5.6.4. South Korea
    • 8.5.6.5. Rest of Asia-Pacific
• 8.6. Middle East and Africa
  • 8.6.1. Introduction
  • 8.6.2. Key Region-Specific Dynamics
  • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape and Market Positioning

• 9.1. Competitive Overview and Key Market Players
• 9.2. Market Share Analysis and Positioning Matrix
• 9.3. Strategic Partnerships, Mergers & Acquisitions
• 9.4. Key Developments in Product Portfolios and Innovations
• 9.5. Company Benchmarking

10. Company Profiles

• 10.1. Thermo Fisher Scientific, Inc.*
  • 10.1.1. Company Overview
  • 10.1.2. Product Portfolio
    • 10.1.2.1. Product Description
    • 10.1.2.2. Product Key Performance Indicators (KPIs)
    • 10.1.2.3. Historic and Forecasted Product Sales
    • 10.1.2.4. Product Sales Volume
  • 10.1.3. Financial Overview
    • 10.1.3.1. Company Revenue
    • 10.1.3.2. Geographical Revenue Shares
    • 10.1.3.3. Revenue Forecasts
  • 10.1.4. Key Developments
    • 10.1.4.1. Mergers & Acquisitions
    • 10.1.4.2. Key Product Development Activities
    • 10.1.4.3. Regulatory Approvals, etc.
  • 10.1.5. SWOT Analysis
• 10.2. Merck KGaA
• 10.3. Agilent Technologies, Inc.
• 10.4. GenScript
• 10.5. Creative Biogene
• 10.6. Bio-Rad Laboratories, Inc.
• 10.7. Takara Bio Inc.
• 10.8. QIAGEN
• 10.9. Eurofins Genomics
• 10.10. Synthego

LIST NOT EXHAUSTIVE

11. Assumption and Research Methodology

• 11.1. Data Collection Methods
• 11.2. Data Triangulation
• 11.3. Forecasting Techniques
• 11.4. Data Verification and Validation

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us